Abstract:Background: Hepatocellular carcinoma (HCC) is one of the most lethal cancers with a continuous increase in incidence. Drug resistance limits the therapeutic effects of multi-kinase inhibitor sorafenib for advanced stage HCC patients. Aberrant mitochondrial dynamics and metabolism now are considered as the hallmarks of tumor. Thus, we aimed to clarify the relationship between mitochondrial dynamics and metabolism, as well as explore the combination targeting therapies for sorafenib-resistant HCC.Methods: Mitochondrial morphology was evaluated by immunefluorescent staining. The switch of mitochondrial metabolism was evaluated by oxygen consumption ratio (OCR), glucose uptake and lactate production. The expression of Drp1 was determined by immunohistochemical staining, Western blot and real-time PCR. Cell counting, colony formation and cell cycle assays were performed to assess cell growth in vitro. In addition, time-lapse cell motility assay and transwell assay were used to evaluate cell migration and invasion capacities. The orthotopic xenograft models were used to illustrated the therapeutic effects of combinative administration of OXPHOS inhibitor IACS-010759 with Drp1 inhibitor mdivi-1.Results: In this study, Drp1-mediated mitochondrial fission and hyper-glycolytic phenotype were dominant in sorafenib-resistant HCC cells, which were closely correlated with tumor prognosis. Drp1 knockdown or inhibitor could impair the invasive and metastatic capacities, but promoted cell cycle and cellular growth, which was due to metabolic shift from aerobic glycolysis to oxidative phosphorylation (OXHOPS). Additional administration of OXPHOS inhibitor IACS-010759 combined with Drp1 inhibitor mdivi-1, alleviated the tumor progression of sorafenib-resistant HCC remarkably in both proliferation and metastasis.Conclusions: This study suggests that mitochondrial dynamics deeply influenced mitochondrial metabolism in sorafenib-resistant HCC cells, which exhibit more aggressive hybrid metabolic phenotype. Combination of targeting mitochondrial dynamics and metabolism may be an effective approach for overcoming sorafenib resistance of hepatocellular carcinoma.Funding: This work was supported by the Natural Science Foundation of Guangdong Province (1914050004928), Sanming Project of Medicine in Shenzhen (No. SZSM202011010) and Sanming Project of Medicine in Shenzhen (No. SZSM201911008).Declaration of Interest: All the authors declare no conflict of interest.Ethical Approval: The present study was performed abiding by the Helsinki Declaration and carried out under the approval of the Ethics Committee of Guangdong General Hospital.

Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells

Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.

Hypoxia Induces Sorafenib Resistance Mediated by Autophagy Via Activating FOXO3a in Hepatocellular Carcinoma

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats

Involvement of Reactive Oxygen Species in Sorafenib-Induced Autophagy in HepG2 Cells

Role of sirtuin 1 (SIRT1) in regulation of autophagy and nuclear factor-kappa Beta (NF-ĸβ) pathways in sorafenib-resistant hepatocellular carcinoma (HCC)

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation

PLEKHG5, Stabilized by HDAC2-Related Deacetylation, Confers Sorafenib Resistance Through Regulating Rac1/AKT/NF-κB Signaling in HCC

Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma

Regulation of Glycolytic Metabolism by Autophagy in Liver Cancer Involves Selective Autophagic Degradation of HK2 (hexokinase 2)

Upregulation of HIF-2α Induced by Sorafenib Contributes to the Resistance by Activating the TGF-α/EGFR Pathway in Hepatocellular Carcinoma Cells

Glycolysis maintains AMPK activation in sorafenib-induced Warburg effect

Effect and mechanism of sorafenib in inhibiting autophagy of HepG_2 cells proliferation

Combination of Metformin and Sorafenib Suppresses Proliferation and Induces Autophagy of Hepatocellular Carcinoma Via Targeting the Mtor Pathway.

Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells

Combination of Targeting Mitochondrial Dynamics and Metabolism Reverses the Acquired Resistance to Sorafenib in Hepatocellular Carcinoma

AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance Via the Promotion of Autophagy.

PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib